Eleva’s innovative pipeline addresses rare diseases and complement-related disorders.

Our therapies are powered by our unique moss-based manufacturing system.

Positive preclinical and clinical data support our current projects and have validated our platform.

Eleva strives to bring novel therapies to patients in need together with partners as well as independently. We harness the outstanding capabilities of our moss-based expression platform to create candidates few or no one else can and advance them into clinical development.

Numerous examples exist for biologics with potentially transformative therapeutic value that are neglected because they cannot be produced at scale, or the used expression system doesn’t provide a product with best-in-class properties.

We are constantly exploring new opportunities to unlock and enable such unique biopharmaceuticals in our industry. We partner selectively to initiate new programs and move towards market approval. Our current two proprietary programs in development are:

Our Factor H Program Moving Towards Phase 1

Eleva has achieved preclinical proof-of-concept and is advancing its program into clinical development in C3G.

Our Fabry Disease Program in Clinical Phase 1/2

Eleva has concluded a Phase 1b study and is evaluating partnerships for the next development steps.

  • Uptake of moss‐derived human recombinant GAA in Gaa−/− mice

    Hintze S, Dabrowska-Schlepp P, Berg B, Graupner A, Busch A, Schaaf A, Schoser B, Meinke P

  • Moss-produced human complement factor H with modified glycans has an extended half-life and improved biological activity

    Tschongov T, Konwar S, Busch A, Sievert C, Hartmann A, Noris M, Gastoldi S, Aiello S, Schaaf A, Panse J, Zipfel PF, Dabrowska-Schlepp P, Häffner K

  • Comparison of efficacy between subcutaneous and intravenous application of moss-aGal in the mouse model of Fabry disease

    Dabrowska-Schlepp P, Busch A, Shen JS, Cheong RY, Madsen LB, Mascher D, Schiffmann R, Schaaf A

  • Moss-Derived Human Recombinant GAA Provides an Optimized Enzyme Uptake in Differentiated Human Muscle Cells of Pompe Disease

    Hintze S, Limmer S, Dabrowska-Schlepp P, Berg B, Krieghoff N, Busch A, Schaaf A, Meinke P, Schoser B

  • Pharmacokinetics, pharmacodynamics, and safety of moss‐aGalactosidase A in patients with Fabry disease

    Hennermann JB, Arash-Kaps L, Fekete G, Schaaf A, Busch A, Frischmuth T

  • Mannose receptor-mediated delivery of moss-made α-galactosidase A efficiently corrects enzyme deficiency in Fabry mice

    Shen JS, Busch A, Day TS, Meng XL, Yu CI, Dabrowska-Schlepp P, Fode B, Niederkrüger H, Forni S, Chen S, Schiffmann R, Frischmuth T, Schaaf A

  • Treatment of experimental C3 Glomerulopathy by human complement factor H produced in glycosylation-optimized Physcomitrella patens

    Häffner K, Parsons J, Bohlender LL, Hörnstein S, Niederkrüger H, Fode B, Busch A, Krieghoff N, Koch J, Schaaf A, Frischmuth T, Zipfel PF, Pohl M, Reski R, Decker E, Michelfelder S

  • Moss-Produced, Glycosylation-Optimized Human Factor H for Therapeutic Application in Complement Disorders

    Michelfelder S, Juliana P, Bohlender LL, Hoernstein S, Niederkrüger H, Busch A, Krieghoff N, Koch J, Fode B, Schaaf A, Frischmuth T, Pohl M, Zipfel PF, Reski R, Decker E, Häffner K

  • CLARIOstar® determines activity of a moss-produced human acid alphaglucosidase (GAA) in a fluorescence-based assay

    Berg B, Fischer A, Hässler F, Dabrowska-Schlepp P, Maurer F, Tintelnot S

  • Jun 13, 2024

    ...will focus on diagnostics and the disease spectrum of C3 Glomerulopathy, zooming in on histological spectrum.

Next Page